Shin­gles vac­cine gives GSK boost

Yorkshire Post - Business - - BUSINESS / NEWS -


Glax­oSmithK­line has up­graded its full-year guid­ance fol­low­ing strong sales of its shin­gles vac­cine.

The group said rev­enue gar­nered from Shin­grix now ex­pected to be be­tween £700m and £750m in 2018, help­ing it pen­cil in earn­ings per share growth of be­tween 8 and 10 per cent.

Pre­vi­ously, GSK ex­pected Shin­grix sales at be­tween £600m and £650m. It came as GSK booked pre-tax profit of £1.71bn in the three months to Septem­ber, broadly un­changed from the year be­fore. Rev­enue grew to £8.09bn from


Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.